EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent advances in understanding the pathogenesis, diagnosis, and treatment of tuberous sclerosis complex (TSC)-associated Lymphangioleiomyomatosis

Zhongchao Gai, Yujiao He, Quanjian Zhao, Xinran Du, Jieqiong Zhao

Biochemical Pharmacology · 2026

DOI: 10.1016/j.bcp.2026.117697 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Zhongchao Gai und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological and Pharmaceutical Sciences, Shaanxi University of Science and Technology, Xi'an 710021, China. Hauptthemen laut MEDLINE: Lymphangioleiomyomatosis, Tuberous Sclerosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 93 Literaturangaben. Gefördert von: Key Research and Development Projects of Shaanxi Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymphangioleiomyomatosis (LAM) is a rare, slowly progressive lung disorder that predominantly affects women of childbearing age. LAM is classified into two subtypes: tuberous sclerosis complex (TSC)-associated LAM (TSC-LAM) and sporadic LAM. Mutations in the TSC1 or TSC2 genes are the underlying cause of both forms. Over the past decade, research and clinical practice in managing LAM have advanced significantly, with breakthroughs in the understanding of disease pathogenesis, biomarker discovery, targeted therapies, and new therapeutic technologies. This article presents a review of the progress in understanding the pathobiology, diagnosis, and treatment of LAM, based on PubMed-indexed studies published from 2015 to 2024. According to the current literature, the activation of mechanistic target of rapamycin (mTOR) signaling is the leading cause of LAM, while other mTOR-independent pathways, such as the sphingosine kinase 1 (SPHK1)/sphingosine-1-phosphate (S1P) and cyclooxygenase 2 (COX2)/prostaglandin E2 (PGE2) pathways, have been hypothesized to play roles in the pathogenesis. The literature suggests that LAM might originate in the uterine and/or pulmonary mesenchymal cells. Advanced imaging methods such as chest high-resolution CT (HRCT) and newly identified LAM biomarkers can aid in improving the diagnostic of LAM. mTOR inhibitors, such as sirolimus, remain the cornerstone therapy, but variable treatment responses highlight the need for personalized approaches. Nevertheless, more studies are needed to better understand LAM, develop more powerful diagnostic, prognostic, and predictive biomarkers, and optimize the current treatments of LAM while developing novel therapeutic approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphangioleiomyomatosisTuberous SclerosisHumansAnimalsMTOR InhibitorsTuberous Sclerosis Complex 2 ProteinTuberous Sclerosis Complex 1 ProteinTOR Serine-Threonine Kinases

Stichwörter der Autor:innen

LungLymphangioleiomyomatosisSirolimusTSCmTOR

Substanzen

MTOR InhibitorsTuberous Sclerosis Complex 2 ProteinTuberous Sclerosis Complex 1 ProteinTOR Serine-Threonine KinasesTSC2 protein, human

Autor:innen und Institutionen

  • School of Biological and Pharmaceutical Sciences, Shaanxi University of Science and Technology, Xi'an 710021, China.
  • Department of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, China. Electronic address: zhaojieqiong1234@163.com.

Förderung

  • Key Research and Development Projects of Shaanxi Province
  • National Natural Science Foundation of China

Zitieren

APA

Gai, Z., He, Y., Zhao, Q., Du, X., & Zhao, J. (2026). Recent advances in understanding the pathogenesis, diagnosis, and treatment of tuberous sclerosis complex (TSC)-associated Lymphangioleiomyomatosis. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.117697

Vancouver

Gai Z, He Y, Zhao Q, Du X, Zhao J. Recent advances in understanding the pathogenesis, diagnosis, and treatment of tuberous sclerosis complex (TSC)-associated Lymphangioleiomyomatosis. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.117697

BibTeX
@article{Gai2026,
  author = {Gai, Zhongchao and He, Yujiao and Zhao, Quanjian and Du, Xinran and Zhao, Jieqiong},
  title = {Recent advances in understanding the pathogenesis, diagnosis, and treatment of tuberous sclerosis complex (TSC)-associated Lymphangioleiomyomatosis},
  journal = {Biochemical Pharmacology},
  year = {2026},
  doi = {10.1016/j.bcp.2026.117697}
}
Kostenlos starten →